A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

• Status: Withdrawn
• Trial end date: 2023-05-11
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

• Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing on this study [for example, nivolumab, pembrolizumab, atezolizumab]

• Participants must be willing to have tumor biopsies

• Participants must have adequate organ function

• Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1

• Participants must be able to swallow tablets

• Participants with stable, previously treated brain metastases may participate if neurologic symptoms have resolved and participants have been off steroids for at least 14 days

Exclusion Criteria:

• Participants must not have moderate or severe cardiovascular disease

• Participants must not have active autoimmune disease (for example Crohn's disease, Hashimotos disease, etc)

• Participants must not have an active infection requiring treatment